IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:

Eva Röjer

GROUP:

1632

SERIAL NO:

10/661,742

EXAMINER: Unknown

FILED:

September 12, 2003

FOR:

REARRANGED SQUAMOUS CELL CARCINOMA ANTIGEN GENES II

Mail Stop: Amendment **Commissioner for Patents** P.O. Box 1450

Alexandria, Virginia 22313-1450

Sir:

RESPONSE TO RESTRICTION REQUIREMENT

In response to the Restriction Requirement of September 4, 2007, Applicants elect the Group XIII, claims 31, 37, 39 and 41 drawn to a method for detecting the SCCA1/SCCA2 fusion protein using Western blotting, an immunoassay for detecting SCCA1/SCCA2 fusion protein, a method for diagnosing the presence or absence of a squamous cell carcinoma by detecting the SCCA1/SCCA2 fusion protein, classified in class 435, subclass 7.1. The Applicants also elect species (b), coded by one of the exons 2-7 of SCCA2 gene fused to exon 8 of the SCCA1 gene, coded by more of the exons 2-7 of SCCA2 gene fused to exon 8 of SCCA1 gene, coded by exon 2-7 of SCCA2 gene fused to exon 8 of SCCA1 gene. Please amend the claims as indicated on the attached sheets. New claims 45-50 have been added in order to more clearly and distinctly define the invention.

This election is made with traverse. Under Article 27 of the Patent Cooperation Treaty, there was no such restriction required in the International application from which the subject application claims priority. Thus with reference to the unity of the invention there is only one invention and all of the claims should be examined together. Examination on the merits is respectfully requested.